Incontinence, Nighttime Urinary, Nocturia, Urge Incontinence, Urinary Frequency More Than Once at Night, Urinary Incontinence, Urinary Incontinence, Urge
Conditions
Keywords
Urinary Incontinence, Urge incontinence, Neurostimulation, Dorsal Genital Nerve, Nocturia
Brief summary
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.
Detailed description
The purpose of the current investigation is to obtain information about the type of stimulation that Ucon provide (time limited vs. urge stimulation), would be the most effective and feasible for the treatment of non-neurogenic OAB symptoms in males.
Interventions
DEVICEUrge stimulation
Participants will receive stimulation for 60 seconds, when they feel an urgency.
DEVICETime limited stimulation
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Sponsors
InnoCon Medical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject is ≥ 18 years of age. 2. Subject is male. 3. Subject is diagnosed with OAB 4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.
Exclusion criteria
1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation). 2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)). 3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection. 4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months. 5. Subject has used antimuscarinics or β3 agonists within 14 days weeks\*. 6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function). 7. Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment. 8. Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation. 9. Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region. 10. Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs. 11. Subject does not speak and understand Dutch. * If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of OAB symptoms in a home setting. | After 44 days (end of study) | Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period. |
| PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of OAB symptoms using UCon in a home setting | Change from baseline at 14 days, 30 days and 44 days (study end) | Ratio of subjects with at least 50% change in their OAB symptoms from baseline. Participants shall complete a 3-day bladder diary to report their symptoms. The symptoms related to OAB: * Urinary urgency is measured by number of urgency episodes/day. * Urinary frequency is measured by number of voidings/day. * Urgency urinary incontinence is measured by number of leaks preceded by urgency/day. * Nocturia is measured by number of voidings/night. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SECONDARY SAFETY: To evaluate the severity of adverse events associated with the use of UCon during the investigational period. | After 44 days (study end) | Severity of adverse events and anticipated adverse device effects.The severity will be evaluated from the subjects' report on any experience associated with the use of UCon. |
| SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life. | Change from baseline at 14 days and 44 days (end of study) | Ratio of subjects with a change in their OAB quality of life measures as assessed by specific QoL questionnaires related to OAB condition (ICIQ-OAB, AOBq). An overall score with greater values indicates a worse symptom outcome. |
| SECONDARY PERFORMANCE: To evaluate the device and treatment acceptability of UCon. | After 44 days (study end) | Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period. |
| SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their treatment outcome (i.e. symptoms) after therapy. | Change from baseline at 14 days and 44 days (end of study) | Ratio of subjects with a change in their treatment outcome (i.e. symptoms) assessed by the 7-point Patient Global Impression of Improvement (PGI-I) scale. Higher scores indicates a worse treatment outcome. |
| SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period. | After 44 days (end of study) | Number of subjects experiencing adverse events and anticipated adverse device effects. Subjects will report on any experience associated with the use of UCon. |
Countries
Netherlands
Contacts
Primary ContactDianna Mærsk Knudsen
Outcome results
None listed